We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NTRA & Diakonos Partner to Use Signatera in Refractory Melanoma Trial
Read MoreHide Full Article
Key Takeaways
NTRA will deploy Signatera in Diakonos' DOC-RM Phase I/II trial for refractory melanoma.
Signatera will track ctDNA over multiple timepoints as DOC1021 tests dendritic cell immunotherapy.
NTRA stock rose 4.4% since Friday's news, as ctDNA monitoring may clarify response when imaging falls short.
Natera (NTRA - Free Report) recently announced a collaboration with Diakonos Oncology to incorporate its Signatera molecular residual disease test into Diakonos’ DOC-RM Phase I/II investigational immunotherapy trial for patients with refractory melanoma.
Management stated that Signatera is well suited to help biopharmaceutical companies evaluate molecular responses throughout treatment. The collaboration with Diakonos could generate deep insight into treatment response dynamics over time by tracking minimal residual disease (MRD) at multiple stages, potentially supporting the future development of treatments for difficult cancers.
Likely Trend of NTRA Stock Following the News
Shares of NTRA have gained 4.4% since the announcement on Friday. In the year-to-date period, shares of the company have fallen 2.5% compared with the industry’s 9.8% decline. However, the S&P 500 has risen 11.1% in the same timeframe.
In the long run, the collaboration strengthens Natera’s position in precision oncology and biopharma research by expanding the application of Signatera in clinical-stage immunotherapy programs. The partnership provides Natera with an opportunity to demonstrate the value of ctDNA monitoring in difficult-to-treat cancers, where traditional radiographic assessments may not fully capture treatment response. The initiative also supports Natera’s strategy of increasing adoption of Signatera across drug development programs and advancing the use of molecular diagnostics to guide personalized cancer care.
NTRA currently has a market capitalization of $31.99 billion.
Image Source: Zacks Investment Research
More on the News
The DOC-RM trial, which started enrolling patients in May, is evaluating DOC1021 (dubodencel), Diakonos’ personalized dendritic cell immunotherapy that received FDA Fast Track designation for unresectable or metastatic cutaneous melanoma. Under the partnership, Signatera will be used to monitor circulating tumor DNA (ctDNA) over multiple timepoints.
While immunotherapies have improved outcomes for patients with advanced melanoma, a substantial proportion of patients fail to respond or later develop treatment resistance. The collaboration targets this unmet need in refractory melanoma. In addition, evaluating treatment response through imaging can be difficult in patients receiving immunotherapy. As a result, longitudinal monitoring of ctDNA may offer earlier and more precise insights into molecular response and disease progression during treatment.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the minimal residual disease (MRD) testing market was valued at $1.70 billion in 2025 and is expected to witness a CAGR of 12% through 2034.
Factors like the demand for highly sensitive technologies like next-generation sequencing (NGS) and digital PCR (dPCR), which accurately detect minimal residual cancer cells to guide treatment decisions and predict patient outcomes, are boosting the market’s growth.
Other News
Natera recently announced the FDA approval of Signatera CDx as a companion diagnostic (CDx) for use with adjuvant atezolizumab (Tecentriq) immunotherapy in patients with muscle-invasive bladder cancer (MIBC). The approval marks the first companion diagnostic approval in the blood-based minimal residual disease (MRD) testing space and represents a major milestone in personalized oncology care.
West Pharmaceutical, sporting a Zacks Rank #1 (Strong Buy) at present, reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Globus Medical, currently sporting a Zacks Rank #1, reported first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.
Globus Medical has an estimated long-term earnings growth rate of 10.2%. GMED’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
Biodesix, currently carrying a Zacks Rank of 2 (Buy), reported a first-quarter 2026 adjusted loss per share of 81 cents, which came narrower than the Zacks Consensus Estimate by 35.7%. Revenues of $26 million beat the Zacks Consensus Estimate by 12.3%.
BDSX has an estimated earnings growth rate of 36% for 2026. The company beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 25.5%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
NTRA & Diakonos Partner to Use Signatera in Refractory Melanoma Trial
Key Takeaways
Natera (NTRA - Free Report) recently announced a collaboration with Diakonos Oncology to incorporate its Signatera molecular residual disease test into Diakonos’ DOC-RM Phase I/II investigational immunotherapy trial for patients with refractory melanoma.
Management stated that Signatera is well suited to help biopharmaceutical companies evaluate molecular responses throughout treatment. The collaboration with Diakonos could generate deep insight into treatment response dynamics over time by tracking minimal residual disease (MRD) at multiple stages, potentially supporting the future development of treatments for difficult cancers.
Likely Trend of NTRA Stock Following the News
Shares of NTRA have gained 4.4% since the announcement on Friday. In the year-to-date period, shares of the company have fallen 2.5% compared with the industry’s 9.8% decline. However, the S&P 500 has risen 11.1% in the same timeframe.
In the long run, the collaboration strengthens Natera’s position in precision oncology and biopharma research by expanding the application of Signatera in clinical-stage immunotherapy programs. The partnership provides Natera with an opportunity to demonstrate the value of ctDNA monitoring in difficult-to-treat cancers, where traditional radiographic assessments may not fully capture treatment response. The initiative also supports Natera’s strategy of increasing adoption of Signatera across drug development programs and advancing the use of molecular diagnostics to guide personalized cancer care.
NTRA currently has a market capitalization of $31.99 billion.
Image Source: Zacks Investment Research
More on the News
The DOC-RM trial, which started enrolling patients in May, is evaluating DOC1021 (dubodencel), Diakonos’ personalized dendritic cell immunotherapy that received FDA Fast Track designation for unresectable or metastatic cutaneous melanoma. Under the partnership, Signatera will be used to monitor circulating tumor DNA (ctDNA) over multiple timepoints.
While immunotherapies have improved outcomes for patients with advanced melanoma, a substantial proportion of patients fail to respond or later develop treatment resistance. The collaboration targets this unmet need in refractory melanoma. In addition, evaluating treatment response through imaging can be difficult in patients receiving immunotherapy. As a result, longitudinal monitoring of ctDNA may offer earlier and more precise insights into molecular response and disease progression during treatment.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the minimal residual disease (MRD) testing market was valued at $1.70 billion in 2025 and is expected to witness a CAGR of 12% through 2034.
Factors like the demand for highly sensitive technologies like next-generation sequencing (NGS) and digital PCR (dPCR), which accurately detect minimal residual cancer cells to guide treatment decisions and predict patient outcomes, are boosting the market’s growth.
Other News
Natera recently announced the FDA approval of Signatera CDx as a companion diagnostic (CDx) for use with adjuvant atezolizumab (Tecentriq) immunotherapy in patients with muscle-invasive bladder cancer (MIBC). The approval marks the first companion diagnostic approval in the blood-based minimal residual disease (MRD) testing space and represents a major milestone in personalized oncology care.
Natera, Inc. Price
Natera, Inc. price | Natera, Inc. Quote
NTRA’s Zacks Rank & Key Picks
Natera currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Globus Medical (GMED - Free Report) and Biodesix (BDSX - Free Report) .
West Pharmaceutical, sporting a Zacks Rank #1 (Strong Buy) at present, reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Globus Medical, currently sporting a Zacks Rank #1, reported first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.
Globus Medical has an estimated long-term earnings growth rate of 10.2%. GMED’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
Biodesix, currently carrying a Zacks Rank of 2 (Buy), reported a first-quarter 2026 adjusted loss per share of 81 cents, which came narrower than the Zacks Consensus Estimate by 35.7%. Revenues of $26 million beat the Zacks Consensus Estimate by 12.3%.
BDSX has an estimated earnings growth rate of 36% for 2026. The company beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 25.5%.